Clinical Trial Update: Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/Phase 3 trial evaluated the predictive value of the Cytocapacity Test in patients with Hodgkin lymphoma, Non-Hodgkin lymphoma, and multiple …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Snippet

Sponsor: WiSP Wissenschaftlicher Service Pharma GmbH | Conditions: Hodgkin's Disease, Non-Hodgkin Lymphomas | Phase 2, Phase 3 | Status: COMPLETED